This study is testing if an injection of Exparel (bupivacaine), a non-opioid pain reliever, can help people with craniofacial pain, including migraines, cluster headaches, and other severe head pains. Researchers will inject Exparel or a saline placebo into the side of the nose using a special camera (endoscope). The goal is to see if Exparel can reduce your pain score over 21 days. You may be able to join if you are 18-80 years old, have craniofacial pain, and have had a visit to the Stanford Pain & ENT clinic. The study is currently unclear on its recruitment status and plans to enroll 15 participants.

Study design

This is a randomized, double-blinded, placebo-controlled, and cross-over study involving about 15 participants. This means you will randomly receive either Exparel or a placebo, and neither you nor your doctor will know which you received.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Your pain score will be measured from the start of the study until day 21.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.